Enzon Pharmaceuticals
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1981[1] |
| Headquarters | Piscataway, New Jersey, , United States |
Key people | George W. Hebard III, M.B.A. (CEO, Interim Principal Executive Officer, Interim Chief Operating Officer)
Richard L. Feinstein CPA ( Principal Financial Officer, Principal Accounting Officer) (Dec 31, 2012))[2] |
| Products | Drugs |
| Revenue | $ 34.49M (Dec31, 2013)[3] |
| Website | enzon |
Enzon Pharmaceuticals, Inc. is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet.[4] Its headquarters is now in Piscataway, New Jersey.[5] The company is a publicly traded company on NASDAQ under the symbol "ENZN". It's also doing marketing works in Asia areas such as China. In 2012, the company orally presented in Nanjing, China about the symposium of its drug delivery systems, which help improve therapeutic molecules' pharmaceutical properties.[6]
History
[edit]Enzon Pharmaceuticals, Inc started its earliest business in 1981. Now, the focus of the company is mainly on development and production of drugs for cancer patients with high unmet needs.[7] It is also actively researching on improving the chemical attachment of PEG to help provide antibodies in molecules.[8] In 2010, Enzon Pharmaceuticals, Inc.sold its specialty pharmaceutical business to the sigma-tau Group (sigma-tau).[9][10]
Production
[edit]The products of Enzon Pharmaceuticals, Inc include four principal compounds of different clinical development, as well as several novel mRNA antagonists in preclinical research.[11]
Research & Development
[edit]In July 2012, Enzon Pharmaceuticals presented the result from pre-clinical studies about human interferon-beta-1b (IFN-β-1b) and an anti-TNF-α antibody fragment (Fab) through releasable PEGylation at the 39th Annual Meeting & Exposition of the Controlled Release Society.[12]
In June 2012, Enzon Pharmaceuticals presented the Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors at the 2012 Advances in Neuroblastoma Research Conference.[13] In the same month, the company presented the Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast at the American Society of Clinical Oncology Meeting.[14]
In May 2012, Enzon Pharmaceuticals reached a strategic partnership using Enzon's PEGylation linker technology and PEG-SN38 (EZN-2208) in China.[15]
Corporate affairs
[edit]Stocks
[edit]The ticker symbol for Enzon Pharmaceuticals, Inc is "ENZN", which was traded on NASDAQ.[16]
Scandals
[edit]The company has recently launched a nationwide recall of OMONTYS injection because of reports on serious hypersensitivity reactions, including possible life-threatening anaphylaxis.[17]
References
[edit]- ^ "Business Summary". Retrieved Dec 22, 2013.
- ^ "Company Officers and directors".
- ^ "Company Key Statistics".
- ^ "History". Retrieved Dec 20, 2013.
- ^ "profile". Retrieved Dec 23, 2013.
- ^ "Enzon Announces Two Oral Presentations". Reuters. 8 November 2012. Archived from the original on 27 December 2013. Retrieved Dec 26, 2013.
- ^ "History". Retrieved Dec 20, 2013.
- ^ "Enzon Announces Two Oral Presentations". Reuters. 8 November 2012. Archived from the original on 27 December 2013. Retrieved Dec 26, 2013.
- ^ "Enzon Completes Sale of Specialty Pharmaceutical Business".
- ^ "Company Business Summary".
- ^ "Investors". Retrieved Dec 25, 2013.
- ^ "Enzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting".
- ^ "Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference".
- ^ "Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting".
- ^ "Enzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China" (PDF).
- ^ "Business Summary". Retrieved Dec 22, 2013.
- ^ "SECURITIES AND EXCHANGE COMMISSION". Retrieved Dec 25, 2013.
